Researchers have linked disease-related proteins and genes to identify specific cellular pathways responsible for Alzheimer's genesis and progression. The proteins were gathered from cerebrospinal ...

Researchers have identified a potential treatment for Sandhoff and Tay-Sachs diseases -- two rare, often fatal lysosomal storage disorders that cause progressive damage to nerve cells in the brain and ...

A once-a-day pill that targets the production of the stress hormone cortisol in the brain has the potential to be the “holy ...

Obstructive sleep apnea has been linked to an increased risk of dementia in a new study—and the association was particularly ...

1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Published in JAMA Open Network, the study examined 204 adults aged 65 and older with no prior diagnosis of memory impairment ...

Between 2021 and 2031, more than 1 million additional direct care workers will be needed. This is the largest worker gap of ...

A combination of two “active” therapies may help slow cognitive decline in older adults, especially those with a type of severe depression and a genetic risk of Alzheimer's, a study indicates.

After dosing with Cognition’s CT1812, study reports declines of 95% and higher in subgroup with below-median p-tau217.